Pfizer to Submit COVID-19 Vaccine to FDA for Emergency Use Authorization in Kids Aged 5 to 11

Tags: Currents COVID, covid testing, COVID VACCINE, Family, Media, World News

Currents News Staff

Vaccine maker Pfizer says its latest trial of the COVID-19 vaccine for children ages 5 to 11 showed it is safe and generated a “robust” antibody response.

The company says it plans to submit to the U.S. Food and Drug Administration for emergency use authorization soon.

According to a Pfizer spokesperson, there were no instances of myocarditis, a type of heart inflammation that’s linked with MRNA vaccines.

These are the first such results released for a U.S. COVID-19 vaccine in this age group.

The data hasn’t been peer-reviewed or published yet.